Calcium channel blockers (CCBs) are one of those drug classes that feel “simple” until UWorld starts mixing them with arrhythmias, vasospastic angina, constipation, gingival hyperplasia, and CYP interactions. For Step 1 (and plenty of Step 2), the key is to separate the two major subclasses, know what tissue they prefer (heart vs vessels), and memorize the classic adverse effects + contraindications that show up in stems.
Big Picture: What Are Calcium Channel Blockers?
Calcium channel blockers inhibit L-type (long-lasting) voltage-gated calcium channels, decreasing calcium influx into:
- Cardiac myocytes → ↓ contractility (negative inotropy)
- SA/AV nodal cells → ↓ automaticity and conduction (negative chronotropy, negative dromotropy)
- Vascular smooth muscle → vasodilation → ↓ systemic vascular resistance (afterload)
Two high-yield families
| Class | Drugs | Main site of action | Primary Step effect |
|---|---|---|---|
| Non-dihydropyridines | Verapamil, Diltiazem | Heart > vessels | ↓ HR, ↓ AV conduction, ↓ contractility |
| Dihydropyridines (“-dipines”) | Amlodipine, Nifedipine, Nicardipine, Clevidipine, Nimodipine, Felodipine, Isradipine | Vessels > heart | Arteriolar vasodilation → ↓ afterload |
Classic memory hook:
- Non-dihydros = “NO” node conduction (AV node)
- Dihydros = “Dilate” peripheral arterioles
Mechanism & Pathophysiology (How They Change Hemodynamics)
L-type calcium channels: where they matter
- SA/AV node depolarization depends on calcium influx (Phase 0 in nodal tissue is Ca²⁺-mediated)
- Vascular smooth muscle contraction depends on Ca²⁺-calmodulin → MLCK activation
- Cardiac contractility depends on Ca²⁺ entry triggering Ca²⁺-induced Ca²⁺ release from SR
What happens when you block them?
Non-dihydropyridines (verapamil, diltiazem)
- ↓ SA node firing → bradycardia
- ↓ AV node conduction → increased PR interval, rate control in atrial arrhythmias
- ↓ Contractility → can worsen HFrEF
Dihydropyridines (e.g., amlodipine, nifedipine)
- Potent arteriolar vasodilation → ↓ SVR → ↓ BP
- Less direct effect on AV node, but can cause reflex tachycardia (especially shorter-acting agents like nifedipine)
Clinical Uses (What They’re For on Exams)
Hypertension
- Dihydropyridines are a mainstay for chronic HTN (e.g., amlodipine)
- Helpful in:
- Older patients
- Black patients (often effective first-line along with thiazides)
- Patients needing strong afterload reduction
Angina
| Type of angina | Why CCBs help | HY note |
|---|---|---|
| Stable angina | ↓ afterload (dipines) and/or ↓ myocardial O₂ demand (non-dipines) | Often combined with nitrates, beta blockers depending on scenario |
| Vasospastic (Prinzmetal) angina | Direct coronary vasodilation | CCBs are first-line (plus nitrates). Avoid isolated nonselective beta blockers |
Arrhythmias (rate control)
- Atrial fibrillation/flutter (rate control): verapamil or diltiazem
- Works by slowing AV nodal conduction → ventricular rate slows
Step trap: If the patient has HFrEF, be cautious—non-dihydropyridines can worsen systolic dysfunction due to negative inotropy.
Subarachnoid hemorrhage (SAH) vasospasm prevention
- Nimodipine reduces risk of delayed cerebral ischemia after SAH.
Hypertensive emergencies (IV options)
- Nicardipine and clevidipine are used IV for rapid BP control.
Clinical Presentation: What Side Effects Look Like in Vignettes
Dihydropyridines (vasodilators)
Think: “too much vasodilation”
- Peripheral edema (ankle swelling)
- Mechanism: preferential arteriolar dilation → increased capillary hydrostatic pressure → fluid extravasation
- Flushing
- Headache
- Dizziness
- Reflex tachycardia (more with short-acting nifedipine)
Non-dihydropyridines (cardiac depressants)
Think: “too much AV node block”
- Bradycardia
- AV block
- Worsening heart failure (negative inotropy)
- Constipation (especially verapamil)
Shared/classic association
- Gingival hyperplasia
- Often tested as: “patient on a BP med with swollen gums”
Diagnosis & Monitoring (What You’re Expected to Recognize)
CCBs are usually a clinical diagnosis (you recognize the drug effect), not something you “test” for—but Step questions commonly point to:
ECG changes (non-dihydropyridines)
- PR prolongation due to slowed AV conduction
- AV block patterns in toxicity
Vitals and symptoms
- Hypotension (both classes)
- Bradycardia (more with verapamil/diltiazem)
- Edema (more with dipines)
Toxicity clues (big Step 1 favorite)
- Patient with overdose + hypotension + bradycardia + hyperglycemia
- CCB toxicity reduces insulin release (Ca²⁺-dependent) → hyperglycemia
Treatment & Clinical Management (Including Toxicity)
Routine prescribing pearls
- Avoid non-dihydropyridines in HFrEF (can worsen)
- Be careful combining non-dihydropyridines + beta blockers → excessive AV node suppression (bradycardia/heart block)
CCB overdose management (high yield)
Support ABCs plus targeted antidotes:
- IV calcium (calcium gluconate or calcium chloride)
- High-dose insulin therapy (improves inotropy and metabolism; treat hyperglycemia)
- Vasopressors (e.g., norepinephrine) for refractory hypotension
- Glucagon is classically for beta-blocker toxicity, but sometimes used adjunctively; the key association for CCBs is calcium + high-dose insulin.
HY Contraindications, Warnings, and Drug Interactions
Contraindications / caution
- Non-dihydropyridines:
- HFrEF (negative inotropy)
- AV block, sick sinus syndrome (unless paced)
- Caution with bradycardia
Interaction traps
- Non-dihydropyridines inhibit CYP3A4 and P-glycoprotein (clinically relevant)
- Can increase levels of other drugs (classically statins, cyclosporine, etc., depending on context)
- Additive effects with other negative chronotropes:
- Beta blockers
- Digoxin (also affects AV node)
Rapid “Which CCB Do I Pick?” Scenarios
| Scenario | Best CCB association | Why |
|---|---|---|
| AF with rapid ventricular response needing rate control | Diltiazem/verapamil | AV nodal slowing |
| HTN with ankle edema after starting amlodipine | Dihydropyridine AE | Arteriolar dilation → edema |
| SAH patient in ICU to prevent vasospasm | Nimodipine | Cerebral vasospasm prevention |
| Chest pain at rest with transient ST elevations (Prinzmetal) | Dihydropyridine (or diltiazem) | Coronary vasodilation |
| Constipation + bradycardia on BP med | Verapamil | Non-dihydro AE pattern |
First Aid Cross-References (What to Tie Together)
Use these as “mental hyperlinks” while you study:
- Cardiovascular Pharmacology – Antihypertensives: CCB classes, MOA, adverse effects (edema, flushing, headache; gingival hyperplasia; constipation with verapamil).
- Antianginal drugs: CCBs for stable and Prinzmetal angina.
- Antiarrhythmics (rate control): Class IV antiarrhythmics = verapamil/diltiazem (AV node).
- Toxicology/Overdose principles: hypotension/bradycardia + hyperglycemia in CCB overdose; treat with IV calcium and high-dose insulin.
(Exact page numbers vary by edition—anchor these to the Antihypertensives, Antianginals, and Antiarrhythmics sections.)
Ultra–High-Yield Checklist (If You Only Remember 10 Things)
- Two classes: non-dihydros (verapamil, diltiazem) vs dihydros (-dipines).
- Non-dihydros act on the heart → ↓ HR, ↓ AV conduction, ↓ contractility.
- Dihydros act on vessels → arteriolar vasodilation → ↓ afterload.
- Prinzmetal angina: treat with CCBs (and nitrates).
- AF/flutter rate control: diltiazem/verapamil.
- Nimodipine prevents SAH vasospasm complications.
- Peripheral edema is a classic dihydropyridine adverse effect.
- Constipation + bradycardia screams verapamil.
- Avoid non-dihydros in HFrEF and be cautious with AV block.
- CCB overdose: hypotension + bradycardia + hyperglycemia → treat with IV calcium + high-dose insulin.